← Leaderboards
Martha A Belury
Ohio State University
$2,760,489
Attributed
$3,914,269
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $678.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,914,269 · 9
By mechanism
R01$1,946,846 · 1
R21$1,467,691 · 3
M01$353,008 · 4
R03$146,724 · 1
Top collaborators
- Brian C Clark3 shared
- Subha V Raman3 shared
Most similar at Ohio State University
Same institution · by research overlap
- Rengasayee Veeraraghavan$2,930,210
- Kristin I Stanford$6,188,806
- Daniel Gallego-Perez$4,522,521
- Saame R Shaikh$6,682,858
- Subha V Raman$6,425,679
Others in their field
Top investigators on “Link”
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- David R. Weir · University Of Michigan At Ann Arbor$206,261,870
- Clare E Reimers · Gordon Research Conferences$205,233,456
- Demian A Bailey · Oregon State University$205,233,456
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
Research focus
LinkPreventTissuesReportingWomanDietAffectObesityMuscle FormMitochondriaMuscle FunctionMuscleAdultEventDouble-Blind MethodSourceOilsPhysical ActivityBody Weight DecreasedPlacebosSupplementationInsulin SensitivityAdverse EffectsAdipocytes
Grant awards (21)
Improving sarcopenia by targeting mitochondria$621,404
R01 · FY2025 · AG · contact PI
Improving sarcopenia by targeting mitochondria$646,684
R01 · FY2024 · AG · contact PI
Improving sarcopenia by targeting mitochondria$678,758
R01 · FY2023 · AG · contact PI
Dietary fats, mitochondrial function and muscle health in cancer patients$107,055
R21 · FY2020 · CA · contact PI
Dietary fats, mitochondrial function and muscle health in cancer patients$54,004
R21 · FY2019 · CA · contact PI
Dietary fats, mitochondrial function and muscle health in cancer patients$199,655
R21 · FY2018 · CA · contact PI
PDQ6: Loss of adiponectin as a contributing factor in cancer cachexia$164,014
R21 · FY2015 · CA · contact PI
Naringenin modulation of sarcopenia in mice$99,949
R21 · FY2015 · CA · contact PI
PDQ6: Loss of adiponectin as a contributing factor in cancer cachexia$197,624
R21 · FY2014 · CA · contact PI
Bioavailability and activity of dietary naringenin as a chemopreventive agent$71,093
R03 · FY2013 · CA · contact PI
Bioavailability and activity of dietary naringenin as a chemopreventive agent$75,631
R03 · FY2012 · CA · contact PI
Fatty acid supplementation in management of type 2 diabetes$180,099
R21 · FY2009 · AT · contact PI
Fatty acid supplementation in management of type 2 diabetes$63,432
R21 · FY2009 · AT · contact PI
Fatty acid supplementation in management of type 2 diabetes$180,239
R21 · FY2008 · AT · contact PI
MANAGEMENT OF TYPE 2 DIABETES MELLITUS BY CONJUGATED LINOLEIC ACID$7,969
M01 · FY2008 · RR · contact PI
Fatty acid supplementation in management of type 2 diabetes$221,620
R21 · FY2007 · AT · contact PI
MANAGEMENT OF TYPE 2 DIABETES MELLITUS BY CONJUGATED LINOLEIC ACID$137,449
M01 · FY2007 · RR · contact PI
MANAGEMENT OF TYPE 2 DIABETES MELLITUS BY CONJUGATED LINOLEIC ACID (CLA)$185,351
M01 · FY2006 · RR · contact PI
MANAGEMENT OF TYPE 2 DIABETES MELLITUS BY CONJUGATED LINOLEIC ACID (CLA)$15,757
M01 · FY2005 · RR
DIETARY MANAGEMENT OF GESTATIONAL DIABETES$4,669
M01 · FY2005 · RR
Dietary Management of Gestational Diabetes$1,813
M01 · FY2004 · RR